Consensus of official position of IOF/ISCD FRAX initiatives in Asia-Pacific region

Wu CH 1 , McCloskey EV 2 , Lee JK 3 , Itabashi A 4 , Prince R 5 , Yu W 6 Show all authors , Li-Yu J 7 , Chionh SB 8 , Zhao Y 9 , Shin CS 10 , Gunawan T 11 , Tsai KS 12 , Chieng PU 13 , Changlai SP 14 , Chan DC 15 , Chen JF 16 , Tanner SB 17 , Hans DB 18 , Kanis JA 19 , Chang YF 20 , Sun ZJ 21 , Yang RS 22 , Asia Pacific Panel of ISCD

Affiliations 

  • 1 Department of Family Medicine, National Cheng Kung University Hospital and College of Medicine, Tainan, Taiwan. Electronic address: paulo@mail.ncku.edu.tw
  • 2 Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK
  • 3 Osteoporosis Treatment Centre, Kuala Lumpur, Malaysia
  • 4 SCBR (Saitama Center for Bone Research), Kubojima Clinic, Saitama, Japan
  • 5 Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, Western Australia
  • 6 Department of Radiology, Peking Union Medical College Hospital Beijing, Beijing, China
  • 7 Department of Medicine, University of Santo Tomas Hospital, Manila, Philippines
  • 8 Division of Endocrinology, Department of Medicine, National University Health System, Singapore
  • 9 Obstetrician and Gynecologist in Beijing United Family Hospital, Beijing, China
  • 10 Seoul National University College of Medicine, Seoul, Korea
  • 11 Jakarta Osteoporosis Center, Jakarta, Indonesia
  • 12 Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
  • 13 Osteoporosis Center, Taiwan Adventist Hospital, Taipei, Taiwan
  • 14 Department of Nuclear Medicine and Radiology, Lin Shin Hospital, Taichung, Taiwan
  • 15 Department of Geriatrics and Gerontology, National Taiwan University Hospital, Taipei, Taiwan
  • 16 Division of Endocrinology and Metabolism, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
  • 17 Division of Rheumatology & Allergy, Vanderbilt University Medical Center, Nashville, TN, USA
  • 18 Center of Bone Diseases, Department of Bone & Joint, Lausanne University Hospital, Lausanne, Switzerland
  • 19 WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
  • 20 Department of Family Medicine, National Cheng Kung University Hospital and College of Medicine, Tainan, Taiwan
  • 21 Secction of Family Medicine, Department of Internal Medicine, National Cheng Kung University Hospital Dou-Liou Branch, Douliou City, Taiwan
  • 22 Department of Orthopedics, National Taiwan University Hospital, Taipei, Taiwan
J Clin Densitom, 2014 Jan-Mar;17(1):150-5.
PMID: 23916756 DOI: 10.1016/j.jocd.2013.06.002

Abstract

The fracture risk assessment tool (FRAX(®)) has been developed for the identification of individuals with high risk of fracture in whom treatment to prevent fractures would be appropriate. FRAX models are not yet available for all countries or ethnicities, but surrogate models can be used within regions with similar fracture risk. The International Society for Clinical Densitometry (ISCD) and International Osteoporosis Foundation (IOF) are nonprofit multidisciplinary international professional organizations. Their visions are to advance the awareness, education, prevention, and treatment of osteoporosis. In November 2010, the IOF/ISCD FRAX initiative was held in Bucharest, bringing together international experts to review and create evidence-based official positions guiding clinicians for the practical use of FRAX. A consensus meeting of the Asia-Pacific (AP) Panel of the ISCD recently reviewed the most current Official Positions of the Joint Official Positions of ISCD and IOF on FRAX in view of the different population characteristics and health standards in the AP regions. The reviewed position statements included not only the key spectrum of positions but also unique concerns in AP regions.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications